









Markets
/
Stocks
/
nasdaq-nbtx
/

Nanobiotix SA

NBTX

19.870USD

+0.200+1.02%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

958.02MMarket Cap

--P/E TTM



Nanobiotix SA

19.870

+0.200+1.02%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Nanobiotix SA

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Nanobiotix SA's Score

Industry at a Glance

Industry Ranking

287 / 501

Overall Ranking

521 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Strong Buy

Current Rating

17.400

Target Price

-12.43%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Nanobiotix SA Highlights

StrengthsRisks

Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

Growing

The company is in a growing phase, with the latest annual income totaling USD -10.69M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD -10.69M.

Undervalued

The company’s latest PE is -10.83, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 5.65M shares, decreasing 42.25% quarter-over-quarter.

Held by Baillie Gifford

Star Investor Baillie Gifford holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Nanobiotix SA's Company Valuation

Currency: USD Updated: 2025-10-27

There is no valuation score for this company; the Biotechnology & Medical Research industry's average is 6.98. Its current P/E ratio is -10.83, which is -100.00% below the recent high of 0.00 and -100.99% above the recent low of -21.77.

Score

Industry at a Glance

Previous score

0.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 287/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 9.14, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Nanobiotix SA is 24.00, with a high of 24.70 and a low of 3.50.

Score

Industry at a Glance

Previous score

9.14

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Strong Buy

Current Rating

17.400

Target Price

-12.43%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Nanobiotix SA

NBTX

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 6.67, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 25.36 and the support level at 9.79, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.08

Change

-0.41

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.887

Neutral

RSI(14)

50.371

Neutral

STOCH(KDJ)(9,3,3)

71.576

Neutral

ATR(14)

2.323

High Vlolatility

CCI(14)

14.172

Neutral

Williams %R

44.432

Buy

TRIX(12,20)

-0.349

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

19.266

Buy

MA10

18.634

Buy

MA20

21.632

Sell

MA50

17.425

Buy

MA100

11.935

Buy

MA200

7.791

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 11.71%, representing a quarter-over-quarter decrease of 3.62%. The largest institutional shareholder is Baillie Gifford, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Johnson & Johnson Innovation-JJDC, Inc.

5.62M

Geode Capital Management, L.L.C.

10.18K

Morgan Stanley & Co. International Plc

5.30K

-13.11%

UBS Financial Services, Inc.

4.42K

+47.27%

BNP Paribas Securities Corp. North America

761.00

+15.13%

EverSource Wealth Advisors, LLC

517.00

RBC Capital Markets Wealth Management

125.00

-8.09%

Rhumbline Advisers Ltd. Partnership

33.00

Perceptive Advisors LLC

-100.00%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.70. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.